FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783409950> ?p ?o ?g. }

• W2783409950 endingPage "322" @default.
• W2783409950 startingPage "309" @default.
• W2783409950 abstract "Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on SSAs) during a 12-week double-blind treatment period followed by a 36-week open-label extension (OLE). The primary safety and efficacy endpoints were incidence of treatment-emergent adverse events (TEAEs) and percent change from baseline in 24-h u5-HIAA at week 12. Patients ( N = 76) were randomly assigned (1:1:1) to receive placebo or telotristat ethyl 250 mg or 500 mg 3 times per day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the OLE. Through week 12, TEAEs were generally mild to moderate in severity; 5 (placebo), 1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg) patients experienced serious events, and the rate of TEAEs in the OLE was comparable. At week 12, significant reductions in u5-HIAA from baseline were observed, with Hodges–Lehmann estimators of median treatment differences from placebo of −54.0% (95% confidence limits, −85.0%, −25.1%, P < 0.001) and −89.7% (95% confidence limits, −113.1%, −63.9%, P < 0.001) for telotristat ethyl 250 mg and 500 mg. These results support the safety and efficacy of telotristat ethyl when added to SSAs in patients with CS diarrhea (ClinicalTrials.gov identifier: Nbib2063659)." @default.
• W2783409950 created "2018-01-26" @default.
• W2783409950 creator A5002267567 @default.
• W2783409950 creator A5005448318 @default.
• W2783409950 creator A5011951334 @default.
• W2783409950 creator A5016460804 @default.
• W2783409950 creator A5017947396 @default.
• W2783409950 creator A5018626012 @default.
• W2783409950 creator A5031770911 @default.
• W2783409950 creator A5042494371 @default.
• W2783409950 creator A5042918352 @default.
• W2783409950 creator A5053175288 @default.
• W2783409950 creator A5055143638 @default.
• W2783409950 creator A5065065990 @default.
• W2783409950 creator A5071063887 @default.
• W2783409950 creator A5075068326 @default.
• W2783409950 creator A5081606866 @default.
• W2783409950 creator A5081758034 @default.
• W2783409950 creator A5083493576 @default.
• W2783409950 creator A5083798788 @default.
• W2783409950 date "2018-03-01" @default.
• W2783409950 modified "2023-10-17" @default.
• W2783409950 title "Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial" @default.
• W2783409950 cites W1895863249 @default.
• W2783409950 cites W1898402948 @default.
• W2783409950 cites W1924823541 @default.
• W2783409950 cites W2064201279 @default.
• W2783409950 cites W2080129478 @default.
• W2783409950 cites W2091899277 @default.
• W2783409950 cites W2110726089 @default.
• W2783409950 cites W2125332438 @default.
• W2783409950 cites W2128669850 @default.
• W2783409950 cites W2154488948 @default.
• W2783409950 cites W2163537725 @default.
• W2783409950 cites W2169367608 @default.
• W2783409950 cites W2324643229 @default.
• W2783409950 cites W2337135362 @default.
• W2783409950 cites W2547169111 @default.
• W2783409950 cites W2547287898 @default.
• W2783409950 cites W2590625439 @default.
• W2783409950 cites W2592950930 @default.
• W2783409950 cites W2603291805 @default.
• W2783409950 doi "https://doi.org/10.1530/erc-17-0455" @default.
• W2783409950 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5811631" @default.
• W2783409950 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29330194" @default.
• W2783409950 hasPublicationYear "2018" @default.
• W2783409950 type Work @default.
• W2783409950 sameAs 2783409950 @default.
• W2783409950 citedByCount "98" @default.
• W2783409950 countsByYear W27834099502017 @default.
• W2783409950 countsByYear W27834099502018 @default.
• W2783409950 countsByYear W27834099502019 @default.
• W2783409950 countsByYear W27834099502020 @default.
• W2783409950 countsByYear W27834099502021 @default.
• W2783409950 countsByYear W27834099502022 @default.
• W2783409950 countsByYear W27834099502023 @default.
• W2783409950 crossrefType "journal-article" @default.
• W2783409950 hasAuthorship W2783409950A5002267567 @default.
• W2783409950 hasAuthorship W2783409950A5005448318 @default.
• W2783409950 hasAuthorship W2783409950A5011951334 @default.
• W2783409950 hasAuthorship W2783409950A5016460804 @default.
• W2783409950 hasAuthorship W2783409950A5017947396 @default.
• W2783409950 hasAuthorship W2783409950A5018626012 @default.
• W2783409950 hasAuthorship W2783409950A5031770911 @default.
• W2783409950 hasAuthorship W2783409950A5042494371 @default.
• W2783409950 hasAuthorship W2783409950A5042918352 @default.
• W2783409950 hasAuthorship W2783409950A5053175288 @default.
• W2783409950 hasAuthorship W2783409950A5055143638 @default.
• W2783409950 hasAuthorship W2783409950A5065065990 @default.
• W2783409950 hasAuthorship W2783409950A5071063887 @default.
• W2783409950 hasAuthorship W2783409950A5075068326 @default.
• W2783409950 hasAuthorship W2783409950A5081606866 @default.
• W2783409950 hasAuthorship W2783409950A5081758034 @default.
• W2783409950 hasAuthorship W2783409950A5083493576 @default.
• W2783409950 hasAuthorship W2783409950A5083798788 @default.
• W2783409950 hasBestOaLocation W27834099501 @default.
• W2783409950 hasConcept C126322002 @default.
• W2783409950 hasConcept C142724271 @default.
• W2783409950 hasConcept C197934379 @default.
• W2783409950 hasConcept C204787440 @default.
• W2783409950 hasConcept C27081682 @default.
• W2783409950 hasConcept C2779802037 @default.
• W2783409950 hasConcept C2780580376 @default.
• W2783409950 hasConcept C44249647 @default.
• W2783409950 hasConcept C71924100 @default.
• W2783409950 hasConcept C90924648 @default.
• W2783409950 hasConceptScore W2783409950C126322002 @default.
• W2783409950 hasConceptScore W2783409950C142724271 @default.
• W2783409950 hasConceptScore W2783409950C197934379 @default.
• W2783409950 hasConceptScore W2783409950C204787440 @default.
• W2783409950 hasConceptScore W2783409950C27081682 @default.
• W2783409950 hasConceptScore W2783409950C2779802037 @default.
• W2783409950 hasConceptScore W2783409950C2780580376 @default.
• W2783409950 hasConceptScore W2783409950C44249647 @default.
• W2783409950 hasConceptScore W2783409950C71924100 @default.
• W2783409950 hasConceptScore W2783409950C90924648 @default.
• W2783409950 hasIssue "3" @default.
• W2783409950 hasLocation W27834099501 @default.

• next